
C4 Therapeutics, Inc.
NASDAQ:CCCC
2.05 (USD) • At close March 11, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | C4 Therapeutics, Inc. |
Symbool | CCCC |
Munteenheid | USD |
Prijs | 2.05 |
Beurswaarde | 145,528,885 |
Dividendpercentage | 0% |
52-weken bereik | 1.95 - 11.17 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew J. Hirsch M.B.A. |
Website | https://www.c4therapeutics.com |
An error occurred while fetching data.
Over C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)